Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: Results of the PROMISE study

International Journal of Antimicrobial Agents

Volumn 41, Issue 1, 2013, Pages 57-64

  De Waele, J J ^a   Tellado, J M ^b   Alder, J ^c   Reimnitz, P ^d   Jensen, M ^e   Hampel, B ^d   Arvis, P ^d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

^d BAYER PHARMA AG   (Germany)

^e BAYER AG   (Germany)

Author keywords

Complicated intra abdominal infection; Ertapenem; Fluoroquinolones; Moxifloxacin; Randomised controlled trial; Surgery

Indexed keywords

ERTAPENEM; MOXIFLOXACIN; PLACEBO;

ABDOMINAL INFECTION; ADULT; ADVERSE OUTCOME; AMYLASE BLOOD LEVEL; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BACTEROIDES INFECTION; BACTEROIDES THETAIOTAOMICRON; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS AVIUM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION COMPLICATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERRATIA INFECTION; SERRATIA MARCESCENS; SIDE EFFECT; SKIN DISEASE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS CONSTELLATUS; STREPTOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; WOUND INFECTION;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BETA-LACTAMS; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; TREATMENT OUTCOME;

EID: 84871642881     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.08.013     Document Type: Conference Paper

References (30)

1. J. Solomkin, J.E. Mazuski, J.S. Bradley, K.A. Rodvold, E.J.C. Goldstein, and E.J. Baron Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis 50 2010 133 164
2. G. Ackermann, R. Schaumann, B. Pless, M.C. Claros, E.J. Goldstein, and A.C. Rodloff Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria Eur J Clin Microbiol Infect Dis 19 2000 228 232
3. E.J. Goldstein, D.M. Citron, Y.A. Warren, K.L. Tyrrell, C.V. Merriam, and H. Fernandez In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections Antimicrob Agents Chemother 50 2006 148 155
4. C.E. Edmiston, C.J. Krepel, G.R. Seabrook, L.R. Somberg, A. Nakeeb, and R.A. Cambria In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections Antimicrob Agents Chemother 48 2004 1012 1016
5. M. Müller, H. Stass, M. Brunner, J.G. Möller, E. Lackner, and H.G. Eichler Penetration of moxifloxacin into peripheral compartments in humans Antimicrob Agents Chemother 43 1999 234 249
6. A.D. Rink, H. Stass, H. Delesen, D. Kubitza, and K.H. Vestweber Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess Clin Drug Investig 28 2008 71 79
7. H. Stass, A.D. Rink, H. Delesen, D. Kubitza, and K.H. Vestweber Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis J Antimicrob Chemother 58 2006 693 696
8. M.A. Malangoni, J. Song, J. Herrington, S. Choudhri, and P. Pertel Randomized controlled trial of moxifloxacin compared with piperacillin- tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections Ann Surg 244 2006 204 211
9. G. Weiss, R. Reimnitz, B. Hampel, E. Muehlhofer, and H. Lippert Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA study) J Chemother 21 2009 170 180
10. J. Solomkin, Y.P. Zhao, E.L. Ma, M.J. Chen, B. Hampel DRAGON Study Team Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections Int J Antimicrob Agents 34 2009 439 445
11. S.P. Hawser, S.K. Bouchillon, D.J. Hoban, and R.E. Badal Epidemiologic trends, occurrence of extended-spectrum β-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study Surg Infect (Larchmt) 11 2010 371 378
12. J.S. Solomkin, A.E. Yellin, O.D. Rotstein, N.V. Christou, E.P. Dellinger, and J.M. Tellado Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trial Ann Surg 237 2003 235 245
13. N. Namias, J.S. Solomkin, E.H. Jensen, J.E. Tomassini, and M.A. Abramson Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults Surg Infect (Larchmt) 8 2007 15 28
14. ® 400 mg/250 ml solution for infusion. Summary of product characteristics. Bayer plc.; September 2010.
15. ® 1 g powder for concentrate for solution for infusion. Summary of product characteristics. Merck Sharp & Dohme Ltd.; August 2010.
16. M.E. Falagas, G. Peppas, G.C. Makris, D.E. Karageorgopoulos, and D.K. Matthaiou Meta-analysis: ertapenem for complicated intra-abdominal infections Aliment Pharmacol Ther 27 2008 919 931
17. Clinical and Laboratory Standards Institute. Microbiology - MIC. http://www.clsi.org/Content/NavigationMenu/StandardsActivities/ CLSIDocumentsonCAPChecklists/mic.htm [accessed 05.09.2012].
18. J.E. Mazuski Antimicrobial treatment for intra-abdominal infections Expert Opin Pharmacother 8 2007 2933 2945
19. S. Blot, and J. De Waele Critical issues in the clinical management of complicated intra-abdominal infections Drugs 65 2005 1611 1620
20. Y. Golan, L.A. McDermott, N.V. Jacobus, E.J. Goldstein, S. Finegold, and L.J. Harrell Emergence of fluoroquinolone resistance among Bacteroides species J Antimicrob Chemother 52 2003 208 213
21. D.R. Snydman, N.V. Jacobus, L.A. McDermott, R. Ruthazer, Y. Golan, and E.J. Goldstein National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004 Antimicrob Agents Chemother 51 2007 1649 1655
22. H. Wacha, T. Hau, R. Dittner, and C. Ohmann Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group Langenbecks Arch Surg 384 1999 24 32
23. A. Sotto, J.Y. Lefrant, P. Fabbro-Peray, L. Muller, J. Tafuri, and F. Navarro Evaluation of antimicrobial management of 120 consecutive patients with secondary peritonitis J Antimicrob Chemother 50 2002 569 576
24. S. Blot, J.J. De Waele, and D. Vogelaers Essentials for selecting antimicrobial therapy for intra-abdominal infections Drugs 72 2012 e17 e32
25. D.H. Culver, T.C. Horan, R.P. Gaynes, W.J. Martone, W.R. Jarvis, and T.G. Emori Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System Am J Med 91 1991 152S 157S
26. T.C. Horan, R.P. Gaynes, W.J. Martone, W.R. Jarvis, and T.G. Emori CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections Infect Control Hosp Epidemiol 13 1992 606 608
27. G. Markides, D. Subar, and K. Riyad Laparoscopic versus open appendectomy in adults with complicated appendicitis: systematic review and meta-analysis World J Surg 34 2010 2026 2040
28. F. Van Bambeke, and P.M. Tulkens Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes Drug Saf 32 2009 359 378
29. R.J. Andrade, and P.M. Tulkens Hepatic safety of antibiotics used in primary care J Antimicrob Chemother 66 2011 1431 1446
30. J.M. Blondeau What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 63 2009 238 242